Big round · 15 October 2026
OMass Therapeutics raises $310M Series C led by Novo Holdings
OMass Therapeutics, based in United Kingdom, has raised $310M in a Series C led by Novo Holdings, Forbion Capital Partners and Bain Capital Life Sciences, announced on 15 October 2026. 10 other investors joined. It is the 173rd largest equity round we recorded in the twelve months to that date, and the 35th largest Series C of 221. The median Series C over the same period was $100M, so this one is 3.1 times that. Its previous round on record was a Series C of $53M in September 2026.
GBPharma
How big is it?
Against every equity round we recorded in the twelve months to 15 October 2026. Ranks count companies, so the same raise reported twice is counted once.
3.1 times the median Series C of the last twelve months.
Who invested
Novo Holdings32 rounds in the last twelve monthsLed
Forbion Capital Partners20 rounds in the last twelve monthsLed- Bain Capital Life Sciences14 rounds in the last twelve monthsLed
Also in the round
Funding history
- October 2026Series C$310M
- September 2026Series C$53M
- July 2024Series B$44M
- May 2023Series B$13M
- March 2022Round$10M
- August 2021Series A$12M
$442M raised across the 6 rounds we hold.
Reported by
- Jefferson Life Sciences16 October
- MedCity News18 October
The round's figures come from these reports; each link opens the original.
